Literature DB >> 30466974

Eulophia macrobulbon extract relaxes rat isolated pulmonary artery and protects against monocrotaline-induced pulmonary arterial hypertension.

Sutthinee Wisutthathum1, Céline Demougeot2, Perle Totoson3, Kannika Adthapanyawanich4, Kornkanok Ingkaninan5, Prapapan Temkitthawon5, Krongkarn Chootip6.   

Abstract

BACKGROUND: Extract of the wild orchid, Eulophia macrobulbon (EM) inhibits phosphodiesterase5 (PDE5) suggesting it could preferentially dilate the pulmonary vasculature. PURPOSE AND STUDY
DESIGN: To pharmacologically characterize the vascular actions of EM ethanolic extract and its active compound, 1-(4'-hydroxybenzyl)-4,8-dimethoxyphenanthrene-2,7-diol using isolated pulmonary arteries (PA) from rats having pulmonary arterial hypertension (PAH) induced by monocrotaline (MCT). PA were fixed and prepared for histology.
RESULTS: EM extract relaxed PA (EC50 = 0.17  mg/ml, Emax ∼ 94%) but less so for aorta (EC50 = 0.51 mg/ml, Emax ∼ 62%), suggesting some selectivity towards the pulmonary circulation. PA vasorelaxation was reduced by endothelial removal or NG-nitro-L-arginine methyl ester, but unaffected by indomethacin, apamin +charybdotoxin, 4-aminopyridine, glibenclamide, iberiotoxin, or 1H - [1,2,4]oxadiazolo[4,3-a]quinoxalin -1- one. Sodium nitroprusside-induced relaxation was enhanced by EM extract, probably via PDE5 inhibition. EM extract reduced contractions evoked by extracellular Ca2+application, and inhibited intracellular Ca2+release activated by phenylephrine. The phenanthrene relaxed PA independently of the endothelium. MCT thickened walls and decreased lumens of PA, and hypertrophied right ventricular myocytes, effects ameliorated by 3 weeks of oral sildenafil (20  mg/kg) or EM extract (15, 450 or 1000  mg/kg).
CONCLUSION: PAH is improved by EM extract acting through PA relaxation mediated through endothelial NO, reduced Ca2+-mobilization, and reduced PA wall thickness and right ventricular hypertrophy.
Copyright © 2018 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Eulophia macrobulbon; Monocrotaline; Phosphodiesterase 5 inhibitor; Pulmonary arterial hypertension; Pulmonary artery; Vasorelaxation

Mesh:

Substances:

Year:  2018        PMID: 30466974     DOI: 10.1016/j.phymed.2018.05.014

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  4 in total

Review 1.  Traditional Herbal Medicine Discovery for the Treatment and Prevention of Pulmonary Arterial Hypertension.

Authors:  Zhifeng Xue; Yixuan Li; Mengen Zhou; Zhidong Liu; Guanwei Fan; Xiaoying Wang; Yan Zhu; Jian Yang
Journal:  Front Pharmacol       Date:  2021-11-09       Impact factor: 5.810

2.  Vasorelaxant-Mediated Antihypertensive Effect of the Leaf Aqueous Extract from Stephania abyssinica (Dillon & A. Rich) Walp (Menispermaceae) in Rat.

Authors:  Chamberlin Fodem; Elvine Pami Nguelefack-Mbuyo; Magloire Kanyou Ndjenda Ii; Albert Kamanyi; Télesphore Benoit Nguelefack
Journal:  Biomed Res Int       Date:  2021-10-08       Impact factor: 3.411

3.  Phenanthrene-enriched extract from Eulophia macrobulbon using subcritical dimethyl ether for phosphodiesterase-5A1 inhibition.

Authors:  Jukkarin Srivilai; Panatpong Boonnoun; Tongchai Saesong; Chitaporn Pingyod; Nattiya Chaichamnong; Jinutda Engsuwan; Prapapan Temkitthawon; C Norman Scholfield; Nitra Nuengchamnong; Nantaka Khorana; Kornkanok Ingkaninan
Journal:  Sci Rep       Date:  2022-04-09       Impact factor: 4.379

Review 4.  Medicinal Plants and Phytochemicals for the Treatment of Pulmonary Hypertension.

Authors:  Seyed Vahid Jasemi; Hosna Khazaei; Ina Yosifova Aneva; Mohammad Hosein Farzaei; Javier Echeverría
Journal:  Front Pharmacol       Date:  2020-03-12       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.